Evidence map›Paper›PMID 37705495›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy.

Yimin Zheng, Yining Wang, Zhou Lu, Jinkai Wan, Lulu Jiang, Danjun Song, Chuanyuan Wei, Chao Gao, Guoming Shi, Jian Zhou and 4 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  14. Glycolysis enzymes and cellular lactylation in tumour.Clinical and translational medicine · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 3 countries.

Yimin ZhengDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Yining WangDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Zhou LuDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Jinkai WanShanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, P. R. China.
Lulu JiangDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Danjun SongDepartment of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, P. R. China.
Chuanyuan WeiDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Chao GaoDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Guoming ShiDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Jian ZhouDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Jia FanDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Aiwu KeDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.
Lu ZhouDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Jiabin CaiDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai, 200032, P. R. China.ORCID 0000-0002-2930-5532
Fudan University · CNZhejiang Cancer Hospital · CN

Funding

Chen Guang Program of Shanghai Municipal Education CommissionLingang Laboratory LG-QS-202204-04National Natural Science Foundation of China 21877014National Natural Science Foundation of China 22077019National Natural Science Foundation of China 82272703Shanghai Natural Science Foundation 21TQ016Shanghai Natural Science Foundation 21XD1420600Young Elite Scientists Sponsorship Program by CAST 2019QNRC001
6 · The paper itself

Abstract

The combination of immunotherapy and molecular targeted therapy exhibits promising therapeutic efficacy in hepatocellular carcinoma (HCC), but the underlying mechanism is still unclear. Here, phosphoglycerate mutase 1 (PGAM1) is identified as a novel immunometabolic target by using a bioinformatic algorithm based on multiple HCC datasets. PGAM1 is highly expressed in HCC and associated with a poor prognosis and a poor response to immunotherapy. In vitro and in vivo experiments indicate that targeting PGAM1 inhibited HCC cell growth and promoted the infiltration of CD8

Indexed as

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsCD8-Positive T-LymphocytesHumansImmunotherapyPhosphoglycerate MutasePhosphoglycerate Mutasecarcinogen metabolismferroptosishepatocellular carcinomaimmunotherapy

Identifiers

PMID37705495
PMCPMC10582428
OpenAlexW4386725655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.